BSE:WAAREEENER 5 December 2025

March 21, 2026, 1:04 AM EDT. Abbott Laboratories' (ABT) share price has declined 15% year-to-date, trading around US$105, sparking debate on whether it's a value trap or a long-term opportunity. Analysis using discounted cash flow (DCF) models estimates the stock's intrinsic value at approximately $164.42 per share, signalling a potential 35.9% undervaluation. The healthcare giant's recent performance lags peers amid investor caution over medical equipment demand and capital allocation strategies. Analyst forecasts project free cash flow reaching $11.46 billion by 2028, supporting bullish valuation metrics despite recent stock weakness. Investors are advised to consider these fundamentals alongside sector risks when assessing ABT shares.